当前位置: X-MOL 学术Cardiology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Endovascular Transcatheter Aortic Valve Replacement Outcomes in Hypertrophic Cardiomyopathy: Insights from the National Inpatient Sample (2014-2018).
Cardiology ( IF 1.9 ) Pub Date : 2023-05-13 , DOI: 10.1159/000530043
Rohit Vyas 1 , Salik Nazir 1 , Keerat Rai Ahuja 2 , Abdul Mannan Khan Minhas 3 , Ahmed Elzanaty 1 , Tanveer Mir 4 , Mujeeb Sheikh 5
Affiliation  

BACKGROUND Outcomes of patients with hypertrophic cardiomyopathy (HCM) following transcatheter aortic valve replacement (TAVR) remain largely unknown. OBJECTIVES This study sought to assess the clinical characteristics and outcomes of HCM patients following TAVR. METHODS We queried the National Inpatient Sample from 2014 to 2018 for TAVR hospitalizations with and without HCM, creating a propensity-matched cohort to compare outcomes. RESULTS 207,880 patients that underwent TAVR during the study period, 810 (0.38%) had coexisting HCM. In the unmatched population, TAVR patients with HCM compared to those without HCM, were more likely to be female, had a higher prevalence of heart failure, obesity, cancer, and history of pacemaker/implantable cardioverter defibrillation, and were more likely to have nonelective and weekend admissions (p for all <0.05). TAVR patients without HCM had higher prevalence of coronary artery disease, prior percutaneous coronary intervention, prior coronary artery bypass grafting, and peripheral arterial disease compared to their counterparts (p for all <0.05). In the propensity-matched cohort, TAVR patients with HCM had significantly higher incidence of in-hospital mortality, acute kidney injury/hemodialysis, bleeding complications, vascular complications, permanent pacemaker requirement, aortic dissection, cardiogenic shock, and mechanical ventilation requirement. CONCLUSION Endovascular TAVR in HCM patients is associated with an increased incidence of in-hospital mortality and procedural complications.

中文翻译:

肥厚型心肌病的血管内经导管主动脉瓣置换结果:来自全国住院患者样本的见解(2014-2018 年)。

背景 经导管主动脉瓣置换术(TAVR)后肥厚型心肌病(HCM)患者的结果仍然很大程度上未知。目的 本研究旨在评估 TAVR 后 HCM 患者的临床特征和结果。方法 我们查询了 2014 年至 2018 年全国住院患者样本中患有和不患有 HCM 的 TAVR 住院情况,创建了一个倾向匹配队列来比较结果。结果 研究期间 207,880 名接受 TAVR 的患者中,810 名(0.38%)患有 HCM。在未匹配的人群中,与无 HCM 的 TAVR 患者相比,患有 HCM 的 TAVR 患者更有可能是女性,心力衰竭、肥胖、癌症和起搏器/植入式心脏复律除颤史的患病率更高,并且更有可能接受非选择性治疗和周末入场(p 值均<0.05)。与对照组相比,无 HCM 的 TAVR 患者冠状动脉疾病、既往经皮冠状动脉介入治疗、既往冠状动脉旁路移植术和外周动脉疾病的患病率较高(p 均<0.05)。在倾向匹配队列中,患有 HCM 的 TAVR 患者的院内死亡率、急性肾损伤/血液透析、出血并发症、血管并发症、永久起搏器需求、主动脉夹层、心源性休克和机械通气需求的发生率显着较高。结论 HCM 患者的血管内 TAVR 与院内死亡率和手术并发症发生率增加相关。
更新日期:2023-05-13
down
wechat
bug